OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

The rapid at-home COVID-19 test is authorized for ages 2 and up The rapid at-home COVID-19 test is authorized for ages 2 and up

InteliSwab® COVID-19 Rapid Test Selected by Federal Government for Nationwide School Testing

Company Concludes Strategic Alternative Process Given Market Conditions and its Belief in its Ability to Build on Recent Operational Success Company Concludes Strategic Alternative Process Given Market Conditions and its Belief in its Ability to Build on Recent Operational Success

Carrie Eglinton Manner Appointed Chief Executive Officer of OraSure

BETHLEHEM, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 rapid tests detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 subvariants with similar levels of detection to the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta, Gamma and Omicron BA.1. The Omicron sublineage studies were conducted using live SARS-CoV-2 virus at an independent, third-party laboratory and showed InteliSwab® detected the Omicron variants at similar viral load levels, or limit of detection, as previous variants that were tested.

InteliSwab® COVID-19 Rapid Test Validated to Detect the Omicron BA.2, BA.2.12.1, BA.3 and BA.5 Subvariants

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2022 Earnings Conference Call May 10, 2022 5:00 PM ET Company Participants Kathleen Weber - President of Molecular Solutions Lisa Nibauer - President of Diagnostics Nancy Gagliano - Interim Chief Executive Officer & Director Scott Gleason - Senior Vice President of Investor Relations & Corporate Communications and Interim Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Chase Andrew Cooper - Raymond James Frank Takkinen - Lake Street Capital Markets Operator Good afternoon, ladies and gentlemen and welcome to the OraSure Technologies First Quarter Earnings Conference Call. [Operator Instructions] Later, we will conduct a question-and-answer session.

OraSure Technologies, Inc. (OSUR) CEO Nancy Gagliano on Q1 2022 Results - Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates

InteliSwab ® revenue of $22.1 million in Q1, up 50% sequentially with significant scaling in production

OraSure Reports 1Q22 Record Revenue of $67.7 Million; +16% Year-Over-Year With 21% Growth in Non-COVID Revenue

BETHLEHEM, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 first quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, May 10, 2022.

OraSure Technologies, Inc. 2022 First Quarter Earnings Conference Call Tuesday, May 10, 2022, 5:00 p.m. ET

BETHLEHEM, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today its OMNIgene®·GUT Dx (OMD-200) microbiome collection device, has been granted de novo authorization from the U.S. Food and Drug Administration (FDA) and the Company is commercially launching the device.

OraSure Technologies' Subsidiary DNA Genotek Launches the First Device with De Novo Authorization from the FDA for the Preservation and Stabilization of Microbiome Samples

BETHLEHEM, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its' Diversigen subsidiary has launched a new service to provide metatranscriptomic sequencing and analysis of gut microbiome samples.

OraSure Technologies' Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples

OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role

OraSure Technologies, Inc. (OSUR) CEO Stephen Tang on Q4 2021 Results - Earnings Call Transcript

Total 2021 revenue of $233.7 million, up 36% year-over year

OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up

BETHLEHEM, Pa., Feb. 16, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2021 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 23, 2022.

OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET

Shares of OraSure Technologies Inc. OSUR, +5.09% gained 2.2% in premarket trading on Monday after the company said its COVID-19 rapid tests have now been authorized for children between the ages of 2 and 14 years old. The tests had previously received emergency use authorization from the Food and Drug Administration for use in teens and adults.

OraSure said its rapid COVID-19 tests can now be used in children

Data Demonstrates InteliSwab ® is Accurate, Easy to Use, and Well Accepted by Children

InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App

BETHLEHEM, Pa., Jan. 25, 2022 (GLOBE NEWSWIRE) --  OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that it has launched its OraQuick® HIV Self-Test, an oral swab in-home test for HIV-1 and HIV-2, into Europe. The test will be available in six European countries: United Kingdom, Germany, France, Italy, Spain and Portugal.

OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe

BETHLEHEM, Pa., Jan. 13, 2022 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that its InteliSwab® COVID-19 rapid tests detect the Omicron variant as effectively as they detect the original SARS-CoV-2 strain and other previous variants of concern, including Delta, Alpha, Beta and Gamma. The Omicron variant studies were conducted using live SARS-CoV-2 virus at an independent, third-party laboratory and showed InteliSwab® detected the Omicron variant at the same viral load levels, or limit of detection, as previous variants that were tested.

InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants

OraSure Technologies Inc (NASDAQ: OSUR) expects Q4 FY21 revenue at the low end of the Company's guidance range of approximately $60 million. The Company anticipates total InteliSwab revenue of approximately $12 million for Q4 and $20 million for FY21.

OraSure's CEO Resigns, Commences Review Of Strategic Alternatives

Provides Preliminary 4Q21 Financial Outlook

OraSure Technologies Announces Actions to Enhance Stockholder Value

BETHLEHEM, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2022 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on Tuesday, May 17, 2022. The record date for the Meeting will be March 27, 2022. Only stockholders of record as of the close of business on the record date will be entitled to vote at the 2022 Annual Meeting, or any adjournment(s) or postponement(s) of the Meeting. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the Meeting will be provided at a later date.

OraSure Technologies Announces 2022 Annual Meeting Date

Company to Ring Nasdaq Closing Bell and Host Panel Discussions on HIV in New York City Company to Ring Nasdaq Closing Bell and Host Panel Discussions on HIV in New York City

OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus

BETHLEHEM, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests, specimen collection devices, microbiome laboratory and analytical services, today announced that Dr. Stephen S. Tang, President and CEO, will participate in a virtual fireside chat at the Stephens Annual Investment Conference on November 29, 2021 at 12:00 pm ET. Dr. Tang will also speak in a virtual fireside chat at the Evercore 4th Annual HealthConx Virtual Conference on December 1, 2021 at 1:50 pm ET. The conferences will be simultaneously webcast over the Internet.

OraSure Technologies to Present at Upcoming Investor Conferences

BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company's Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack's roles as the new General Counsel, Chief Compliance Officer and Secretary.

OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M.

New Appointments Bring to the Company Significant Executive Leadership, Global Product Development, Public Health, and the Retail Pharmacy Market Experience

OraSure Technologies Appoints Two New Members to the Board of Directors

OraSure Technologies Inc (NASDAQ: OSUR) reported Q3 revenues of $53.92 million, +12% Y/Y, beating the consensus of $47.48 million. Excluding COVID-19 product-related sales, revenues grew by 37%, demonstrating strong growth.

News for OraSure Technologies Stock (OSUR)